Related Experiment Video
Updated: Feb 3, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Small Molecular Leads Differentially Active Against HER2 Positive and Triple Negative Breast Cancer Cell Lines
Adnan Badran1, Atia-Tul-Wahab2, Sharmeen Fayyaz3
1Faculty of Pharmacy and Medicinal Sciences, University of Petra, Amman 1194, Jordan.
Background:
Breast cancer is the most prevalent cancer type in women globally. It is characterized by distinct subtypes depending on different gene expression patterns. Oncogene HER2 is expressed on the surface of cell and is responsible for cell growth regulation. Increase in HER2 receptor protein due to gene amplification, results in aggressive growth, and high metastasis in cancer cells.
Methods:
The current study evaluates and compares the anti-breast cancer effect of commercially available compounds against HER2 overexpressing BT-474, and triple negative MDA-MB-231 breast cancer cell lines.
Results:
Preliminary in vitro cell viability assays on these cell lines identified 6 lead molecules active against breast cancer. Convallatoxin (4), a steroidal lactone glycoside, showed the most potent activity with IC50 values of 0.63 ± 0.56, and 0.69 ± 0.59 µM against BT-474 and MDA-MB-231, respectively, whereas 4-[4-(Trifluoromethyl)-phenoxy] phenol (3) a phenol derivative, and Reserpine (5) an indole alkaloid selectively inhibited the growth of BT-474, and MDA-MB-231 breast cancer cells, respectively.
Conclusion:
These results exhibited the potential of small molecules in the treatment of HER2 amplified and triple negative breast cancers in vitro.
Insights
Small molecules show promise for treating HER2-amplified and triple-negative breast cancers. Convallatoxin demonstrated potent activity against both cancer cell lines in vitro, highlighting potential therapeutic agents.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Breast cancer is the most common cancer in women globally, with distinct subtypes.
- HER2 oncogene amplification drives aggressive growth and metastasis in certain breast cancers.
- HER2 receptor protein on cell surfaces regulates cell growth.
Purpose of the Study:
- To evaluate and compare the anti-breast cancer effects of commercially available compounds.
- To assess compounds against HER2-overexpressing (BT-474) and triple-negative (MDA-MB-231) breast cancer cell lines.
Main Methods:
- In vitro cell viability assays were performed.
- Commercially available compounds were screened.
- Activity was assessed against BT-474 and MDA-MB-231 breast cancer cell lines.
Main Results:
- Six lead molecules with anti-breast cancer activity were identified.
- Convallatoxin (4) exhibited potent activity (IC50: 0.63–0.69 µM) against both cell lines.
- Phenol derivative (3) and Reserpine (5) selectively inhibited BT-474 and MDA-MB-231 cells, respectively.
Conclusions:
- Small molecules demonstrate potential for treating HER2-amplified breast cancer.
- Small molecules show potential for treating triple-negative breast cancer.
- In vitro results highlight promising therapeutic agents for specific breast cancer subtypes.
Related Concept Videos
Positive, Negative, and Zero Work
Positive and Negative Feedback Loops
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Cell Lines
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Molecular Models

